CSIMarket
 
Vbi Vaccines Inc  (VBIV)
Other Ticker:  
 
 
Price: $0.5607 $-0.03 -4.853%
Day's High: $0.5995 Week Perf: -6.55 %
Day's Low: $ 0.56 30 Day Perf: -2.66 %
Volume (M): 45 52 Wk High: $ 4.45
Volume (M$): $ 25 52 Wk Avg: $1.24
Open: $0.57 52 Wk Low: $0.10



 Market Capitalization (Millions $) 12
 Shares Outstanding (Millions) 21
 Employees -
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -115
 Cash Flow (TTM) (Millions $) -48
 Capital Exp. (TTM) (Millions $) 2

Vbi Vaccines Inc
VBI Vaccines Inc. is a biotechnology company that develops and commercializes novel vaccines and immunotherapies for infectious diseases. The company's focus is on developing vaccines for preventing and treating diseases such as hepatitis B, cytomegalovirus, and glioblastoma. VBI Vaccines utilizes their proprietary enveloped virus-like particle (eVLP) platform technology to design and produce vaccines that offer enhanced immune responses. Their innovative approach aims to address unmet medical needs and improve global public health by providing effective and cost-efficient vaccines.


   Company Address: 160 Second Street Cambridge 2142 MA
   Company Phone Number: 830-3031   Stock Exchange / Ticker: NASDAQ VBIV
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Vbi Vaccines Inc

Vbi Vaccines Inc's Spectacular Revenue Surge Shakes the Pharmaceutical Industry, But Profitability Remains Elusive

Exciting Growth in Revenue and EPS Show Promise for VBIV in the Stock Market
VBIV, the leading biopharmaceutical company, has just announced their impressive financial results for the third quarter of 2023. The company reported a remarkable rise in revenue of 1989.59% year on year, reaching an impressive $6.62 million. This growth is a testament to VBIV's dedication and success in the industry.
Despite this tremendous increase in revenue, VBIV also reported widened losses at $-1.01 million. However, it is important to note that the losses have significantly improved in comparison to the previous reporting period. Last year, EPS (Earnings Per Share) stood at $-5.18 per share, while this quarter showed improvement.

Vbi Vaccines Inc

Unprecedented Revenue Surge of 108% in Q2 2023 Sends Shockwaves across Vbi Vaccines Inc

Over the past week, Vbi Vaccines Inc has seen a decline in its shares by 7.41%. However, this drop comes after a remarkable year-to-date performance of 191.31%. Currently, the company's shares are trading on the NASDAQ, 5.4% above its 52-week average.
One factor that may have influenced the recent drop in share prices is the company's announcement of a very robust revenue elevation of 108.092% year on year, amounting to $0.72 million in the fiscal second quarter of 2023. This is certainly an impressive increase, but it was accompanied by an increased loss per share of -$5.18.

Vbi Vaccines Inc

Vbi Vaccines Inc Sees Remarkable Revenue Surge, yet Struggles to Achieve Profitability amidst Overall Losses in Q1 2023

19 vaccines or their implications for the company's financial results.
Vbi Vaccines Inc is experiencing losses in their financial results with a cumulative net loss of $-120 million in the first quarter of 2023. This has resulted in a negative ROI of -101.68%, which is lower than the average ROI of other companies in the Healthcare sector. However, there is some progress seen as the overall ranking of the company's ROI has improved from Q4 2022 to Q1 2023.
Despite the loss, the company has recorded strong revenue growth of 284.921% YoY to $0.49 million during January to March 31, 2023, which is an impressive achievement. However, the loss per share has also increased from $-0.08 per share to $-3.22 per share, indicating a significant challenge that must be addressed.






 

Vbi Vaccines Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com